Abstract 459P
Background
Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer death among males and females. There is evidence that diet habit may influence lung cancer risk. To determine the association between fish intake and dietary polyunsaturated fatty acids (PUFA) and incidence of lung cancer, we identified all available studies to clarify the dose-response relationship between fish and PUFA and lung cancer risk, evaluated the potential effects of frequent fish and PUFA intake on lung cancer mortality, and studied the ability of their supplementations during chemotherapy in patients with lung cancer.
Methods
We systematically reviewed and meta-analyzed the published studies in MEDLINE, EMBASE databases, Cochrane Library database (Cochrane central register of controlled trials) and ClinicalTrials, supplemented with manual screening. Large-scale prospective cohort study and randomized control trials quantifying the associations of fish and PUFA consumption with risk of lung cancer were included. Two investigators dependently assessed studies for inclusion and extracted data on methods, interventions, outcomes and study quality. Relative risk (RR) with 95% confidence interval (CI) was calculated.
Results
13 population-based prospective cohort studies involving 1,785,000 participants and 2 randomized control trials were included. Our study demonstrated that dietary PUFA significant reduced risk of lung cancer for men (RR 0.99, 95%CI 0.98 to 1.00) and USA population (RR 0.99, 95%CI 0.98 to 1.00). Dose-response analysis indicated that a 5g/day increment of dietary PUFA was associated with 5% lower risk of lung cancer (RR 0.95, 95%CI 0.91 to 0.99). In addition, PUFA supplementation is significant improved overall survival in patients with lung cancer (RR 1.98, 95%CI 1.09 to 3.59).
Conclusions
Our study showed an inverse association between dietary PUFA and risk of lung cancer in males and among USA population. Although smoking cessation is the single biggest factor associated with lung cancer risk reduction, this study adds to a growing body of evidence that diet may have a role in modestly reducing lung cancer risk.
Clinical trial identification
Editorial acknowledgement
This work was supported by program for the National Natural Science Foundation of China (grant number 81700025), the Medical and Health Science and Technology Project of Zhejiang (grant number 2018245859), the Medical Science and Technology Plan Projects of Ningbo (grant number 2016A03), the Science Foundation of Zhejiang (grant number LY15H010002) and the Beijing Medical Health Foundation (grant number YWJKJJHKYJJ-HX32).
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
64P - Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Filippo de Braud
Session: Poster display session
Resources:
Abstract
65P - Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster display session
Resources:
Abstract
66P - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew Krebs
Session: Poster display session
Resources:
Abstract
67P - Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
68P - A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck
Presenter: Ming Mo Hou
Session: Poster display session
Resources:
Abstract
69P - Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer
Presenter: Hiroshi Ishikawa
Session: Poster display session
Resources:
Abstract
70P - Is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for cholecystolithiasis combined with common bile duct stones: A meta-analysis
Presenter: Jiasheng Cao
Session: Poster display session
Resources:
Abstract
71P - Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A propensity score analysis
Presenter: Chaobin He
Session: Poster display session
Resources:
Abstract
72P - Novel technique of near-focus mode for accurate operation during endoscopic submucosal tunneling procedure: A two-center comparative study
Presenter: Wei Peng
Session: Poster display session
Resources:
Abstract
73P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models
Presenter: Rachel Sparks
Session: Poster display session
Resources:
Abstract